Ongentys
Active Ingredient(s): OpicaponeFDA Approved: * April 24, 2020
Pharm Company: * NEUROCRINE
Category: Parkinsons
Opicapone, sold under the brand name Ongentys, is a medication which is administered together with levodopa in people with Parkinson's disease.[4] The most common side effects are dyskinesia (difficulty controlling movement), constipation, increased blood creatine kinase, hypotension/syncope, and decreased weight.[3][5] Opicapone, works to restore the levels of dopamine in the parts of the brain that control movement and coordination.[4&... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.